26 Nov 2025 by admin in UncategorizedComments Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
24 Nov 2025 by admin in UncategorizedComments Avenzo Therapeutics Granted Fast Track Designation for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with Urothelial Cancer Previously Treated with Enfortumab Vedotin
19 Nov 2025 by admin in UncategorizedComments Avenzo Therapeutics Announces Appointment of Scott Lipman as Chief Financial Officer
17 Nov 2025 by admin in UncategorizedComments NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts
